HEALTH RELATED QUALITY OF LIFE IN THE DIFFERENT STAGES OF BREAST CANCER IN PATIENTS ATTENDED IN THE SOCIAL SECURITY MEXICAN INSTITUTE
Author(s)
Luz-Ma-Adriana Balderas-Peña, PhD, Clinical Researcher1, Iris Contreras-Hernandez, MSc, MD, Health Economics Researcher2, Jf Mould-Quevedo, PhD, MSc, MBA, Pharmacoeconomics Manager3, Daniel Sat-Muñoz, MD, MSc, Oncologist Surgeon4, Juan Garduño-Espinosa, PhD, MD, Health Economics Researcher2, Gilberto Morgan-Villela, MD, Chief of Oncology Division41Social Security Mexican Institute, pecialties' Hospital. Western National Medical Center, Guadalajara, Mexico; 2 Social Security Mexican Institute, Mexico City, Mexico; 3 Pfizer Mexico, Mexico City, Mexico; 4 Social Security Mexican Institute, Guadalajara, Mexico
OBJECTIVES The aim of this study was to describe health related quality of life in different stages of breast cancer in patients attended in a tertiary referral center at the Social Security Mexican Institute. METHODS Were included outpatients with breast cancer, attended in a tertiary referral center since July to August 2008, with the following inclusion criteria: older than 16 years, breast cancer histological diagnosis, accepted were included through informed consent, were excluded patients with second malignant neoplasm or incomplete information. To calculate health related quality of life EORTC QLQ-C30 score validated Spanish version to México was used; were evaluated global health status, functional scales (physical, role, emotional, cognitive, social) and symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) in scale since 0 to 100 (0=death, 100=perfect health). Were calculated means and range for EORTC QLQ-C30 score items; statistical differences were calculated through ANOVA test, p value <0.05 was considered significant RESULTS We studied 148 breast cancer patients, mean age 51.68±10.32 years old, 69% were married, and 20% had an educational level of preparatory school. The stating of this group was distributed according clinical stage as follow: I-6%, II-23%, III-16%, IV-7% without stage at interview moment (NC) 47% (first visit for diagnosis). Health related quality of life mean for all items was: I:85.7±7, II:75.36±15, III:74.47±17 and IV:61.05±22, NC:76±18 (p=0.07). The assumptions associated with a decreased health related quality of life in relation to late clinical stage were physical function (I-88, II-79, III-75, IV-56; p=0.003), role function (I-90, II-80, III-71, IV-43; p=0.001), weakness (I-83, II-66, III-62, IV-44; p=0.004) and pain (I-85, II-70, III-65, IV-50; p=0.05). CONCLUSIONS We observed decreased health related quality of life in late clinical stage. An important factor with impact in quality life could be adverse events related with adjuvant treatments
Conference/Value in Health Info
2009-05, ISPOR 2009, Orlando, FL, USA
Value in Health, Vol. 12, No. 3 (May 2009)
Code
PCN80
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology